Gotham Asset Management LLC Has $5.37 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Gotham Asset Management LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 386.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,827 shares of the medical equipment provider's stock after buying an additional 40,384 shares during the period. Gotham Asset Management LLC's holdings in Zimmer Biomet were worth $5,369,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. CKW Financial Group raised its holdings in Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock valued at $101,000 after buying an additional 100 shares in the last quarter. Romano Brothers AND Company raised its holdings in Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock valued at $1,000,000 after buying an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its holdings in Zimmer Biomet by 2.3% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after buying an additional 102 shares in the last quarter. M&T Bank Corp raised its holdings in Zimmer Biomet by 0.4% during the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after buying an additional 108 shares in the last quarter. Finally, MGO One Seven LLC increased its stake in shares of Zimmer Biomet by 5.1% in the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 110 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ZBH. JPMorgan Chase & Co. dropped their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Canaccord Genuity Group dropped their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Wells Fargo & Company lowered their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, The Goldman Sachs Group lowered their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $113.45.

Zimmer Biomet Stock Performance

ZBH stock traded up $0.05 during mid-day trading on Friday, hitting $96.78. 2,339,193 shares of the company were exchanged, compared to its average volume of 1,752,324. The business has a 50 day simple moving average of $103.41 and a 200-day simple moving average of $105.87. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $19.15 billion, a PE ratio of 21.75, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.92 and a 1-year high of $121.30.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same period last year, the business posted $1.94 earnings per share. The business's revenue for the quarter was up 1.1% compared to the same quarter last year. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.99%. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.39% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.